MT Newswires
Takeda Says Phase 3 Data Show Potential For Entyvio to Treat Children, Adolescents With Ulcerative Colitis
➖
AI Sentiment
Neutral
5/10
Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) News
Latest updates and market news for TAK
8 news
Feb 14 - Feb 20, 2026
Page 1
Business Wire
Positive Phase 3 Data Demonstrate Potential for ENTYVIO® (vedolizumab) to Address Treatment Gap for Children and Adolescents with Moderate to Severe Ulcerative Colitis
📈
AI Sentiment
Highly Positive
9/10
MT Newswires
Asian Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
📊
AI Sentiment
Positive
6/10
Zacks
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings?
📈
AI Sentiment
Highly Positive
8/10
PR Newswire
HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE
📈
AI Sentiment
Highly Positive
10/10
Simply Wall St.
Assessing Takeda Pharmaceutical (TSE:4502) Valuation After A Strong Run In Recent Months
📈
AI Sentiment
Highly Positive
8/10
Insider Monkey
Alvotech (ALVO) Announces Strong Results for Clinical Trial for AVT80
📈
AI Sentiment
Highly Positive
9/10
Share this news page